![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
Preview |
PDF (supplement)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
| Item Type: | Article |
|---|---|
| Title: | Engineering of PEDF-expressing primary pigment epithelial cells by the SB transposon system delivered by pFAR4 plasmids |
| Creators Name: | Thumann, G., Harmening, N., Prat-Souteyrand, C., Marie, C., Pastor, M., Sebe, A., Miskey, C., Hurst, L., Diarra, S., Kropp, M., Walter, P., Scherman, D., Ivics, Z., Izsvák, Z. and Johnen, S. |
| Abstract: | Neovascular age-related macular degeneration (nvAMD) is characterized by choroidal blood vessels growing into the subretinal space, leading to retinal pigment epithelial (RPE) cell degeneration and vision loss. Vessel growth results from an imbalance of pro-angiogenic (e.g., vascular endothelial growth factor [VEGF]) and anti-angiogenic factors (e.g., pigment epithelium-derived factor [PEDF]). Current treatment using intravitreal injections of anti-VEGF antibodies improves vision in about 30% of patients but may be accompanied by side effects and non-compliance. To avoid the difficulties posed by frequent intravitreal injections, we have proposed the transplantation of pigment epithelial cells modified to overexpress human PEDF. Stable transgene integration and expression is ensured by the hyperactive Sleeping Beauty transposon system delivered by pFAR4 miniplasmids, which have a backbone free of antibiotic resistance markers. We demonstrated efficient expression of the PEDF gene and an optimized PEDF cDNA sequence in as few as 5 x 10(3) primary cells. At 3 weeks post-transfection, PEDF secretion was significantly elevated and long-term follow-up indicated a more stable secretion by cells transfected with the optimized PEDF transgene. Analysis of transgene insertion sites in human RPE cells showed an almost random genomic distribution. The results represent an important contribution toward a clinical trial aiming at a non-viral gene therapy of nvAMD. |
| Keywords: | Neovascular Age-Related Macular Degeneration, Non-Viral Ex Vivo Gene Therapy, Sleeping Beauty Transposon System, PFAR4 Miniplasmids, Primary Pigment Epithelial Cells, Pigment Epithelium-Derived Factor |
| Source: | Molecular Therapy - Nucleic Acids |
| ISSN: | 2162-2531 |
| Publisher: | Nature Publishing Group |
| Volume: | 6 |
| Page Range: | 302-314 |
| Date: | 17 March 2017 |
| Official Publication: | https://doi.org/10.1016/j.omtn.2017.02.002 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
